Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed ...

Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...

According to the scientists, study participants had fewer days to recover from the illnesses when compared to the standard of ...

LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key MetricsFindings Highlight ...

This is based on the continued emergence of bempikibart data in alopecia areata patients with longer-term follow-up from Part A of the SIGNAL-AA Phase 2a clinical trial, the robust pharmacologic ...

Düsseldorf, Germany Wednesday, February 5, 2025, 18:00 Hrs [IST] ...

Shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) climbed 10% following the announcement of a significant clinical response ...

Helsinki-based Aplagon has raised EUR 7 million to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2a clinical trials. Aki Prihti, CEO of Aplagon, said: “We’re delighted to ...

Australian antiviral drug development company Island Pharmaceuticals has completed subject dosing for the phase 2b ...